Evolent Health Closes $166.75M Convertible Notes Sale

Evolent Health ( (EVH) ) just unveiled an update.

On August 18, 2025, Evolent Health, Inc. entered into a purchase agreement with Oppenheimer & Co. Inc. for the issuance and sale of $145.0 million in convertible senior notes due 2031. The private placement closed on August 21, 2025, with a total of $166.75 million in notes issued, generating net proceeds of approximately $161.2 million. The proceeds were used to repurchase $167.4 million of its 1.50% convertible senior notes due 2025 and $40.0 million of its Class A common stock. The notes, issued under an indenture with U.S. Bank Trust Company, are convertible into shares of the company’s stock and have specific terms for conversion and redemption.

The most recent analyst rating on (EVH) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Evolent Health stock, see the EVH Stock Forecast page.

Spark’s Take on EVH Stock

According to Spark, TipRanks’ AI Analyst, EVH is a Neutral.

Evolent Health’s overall stock score reflects significant challenges in financial performance and valuation, with ongoing losses and a negative P/E ratio. However, the company’s strategic initiatives, including AI advancements and new partnerships, provide a positive outlook. The recent corporate event adds financial flexibility, supporting future growth. Technical indicators suggest a bearish trend, which tempers the overall score.

To see Spark’s full report on EVH stock, click here.

More about Evolent Health

Evolent Health, Inc. operates in the healthcare industry, providing healthcare delivery and payment solutions to health systems and physician organizations. The company focuses on transforming clinical and financial outcomes for its clients.

Average Trading Volume: 2,888,028

Technical Sentiment Signal: Sell

Current Market Cap: $1.06B

For an in-depth examination of EVH stock, go to TipRanks’ Overview page.